🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy

RecruitingNAAges 18 Years - 75 YearsFemaleJosephine Connolly-Schoonen
NCT07897344 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will examine if a short-term, reduced protein diet for the 3-day period prior to and on the day of each of the first 4 chemotherapy cycles and 4 days prior to primary breast surgery is well tolerated and adhered to by patients with stage II or III estrogen receptor positive (ER+) human epidermal growth factor receptor negative (HER2-) breast cancer (BC) receiving neoadjuvant chemotherapy (NAC).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 18-75 years of age at time of consent * Stage II or III ER+ HER2- breast cancer patients scheduled to receive standard of care neoadjuvant chemotherapy * Willingness to consume study foods exclusively during the 20 days of prescribed diet Exclusion Criteria: * Any food allergy that may result in anaphylactic response or death (due to possible food allergen cross-contamination in the metabolic kitchen) * Habitual low protein intake, less than or equal to 1.0 g per kilogram adjusted body weight, based on a screening dietary habits questionnaire score * Vegans or vegetarians that consume dairy and or eggs * Pregnant or breastfeeding at the time of screening * Significant mental illness presenting challenges to follow directions and consume the controlled protein diet exclusively * Body mass index less than or equal to 18 kilograms over meter squared or greater than 35 kilograms over meter squared * Participating in another study with a diet intervention
💊

What it tests

  • Dietary Protein Intervention
📍

Where

1 site
Stony Brook Cancer Center
Stony Brook, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy